CHEST Spotlights

 

CHEST Spotlights

Spotlight programs are topic-related education sessions presented at CHEST Annual Meeting 2020. These sessions are presented as prerecorded or live-streamed activities. All sessions will be available on demand to registered attendees throughout the meeting and until January 18, 2021.

After January 18, CHEST will utilize the sessions from the spotlight programs to create certificate programs. Learners must complete a pre- and post-activity assessment to be issued a spotlight certificate for viewing the sessions and completing an activity assessment within that spotlight’s topic. More information will be made available for these programs in January 2021.

  • Treatment of Severe Asthma: Updates From the Guidelines Part 1
  • Evolving Paradigms in the Selection of Biologicals for Severe Asthma
  • Beyond Spirometry: New Developments in the Diagnosis and Assessment of Severe Asthma
  • Treatment of Severe Asthma: The Guidelines and Beyond

Supported in part by an independent medical education grant from Genentech, Inc. and an educational grant from Novartis Pharmaceuticals Corporation.

  • Pro/Con Debate: Uncertainties in Treating COPD
  • Wheezing in Infancy and Risk for Asthma and COPD in Adults
  • Noninvasive Ventilation in Ambulatory COPD
  • Bronchoscopic Lung Volume Reduction: Maximizing the Silver Lining and Minimizing the Storm Clouds
  • Obstructive Lung Diseases in Women: Is There a Difference?
  • Approach to Pulmonary Disease in the Geriatric Patient
  • Big and Breathless: Obesity and Pulmonary Disorders
  • Pulmonary Rehab: Where We’re at and Where We’re Going

Supported in part by an independent educational program from GlaxoSmithKline LLC and an independent medical educational grant from Mylan Specialty L.P.

  • Mock Multidisciplinary Discussion in Interstitial Lung Diseases: To Biopsy or Not
  • Role of Genetics in Pulmonary Fibrosis: Ready for Prime Time?
  • Comorbidities in Interstitial Lung Diseases: An Overlooked Burden
  • CTD-ILD, Overview of The Radiologic Patterns, Treatment Options, and Transplant Outcome
  • HRCT in Fibrotic Interstitial Lung Disease: UIP, IPF, and Beyond
  • Too Much of a Good Thing or Not Enough? Treating Scleroderma With ILD and PH: A Pro-Con Debate
  • Challenges of Diagnosing and Treating Lung Cancer in ILD
  • Lung Cancer in Interstitial Lung Disease: An Emerging Dilemma
  • Rare Interstitial Lung Disease Cases: Choose Your Own Adventure
  • ICU Management of the ILD Patient in Flair: What Should and What Should Not Be Done
  • Oxygen Therapy: Patients’ Perspective Virtual Patient Tour

Supported in part by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, Inc.

  • Eligibility, Dissemination, and Access to Lung Cancer Screening: Challenges and Opportunities
  • A Guideline-Driven Approach to the Challenges of Non-small Cell Lung Cancer Diagnosis and Staging
  • Application of Biomarkers in NSCLC: From Screening to Diagnostics Through Therapeutic Follow-up
  • Oligometastatic Disease: Changing the Long-Term Management of Metastatic Lung Cancer
  • Effect of Frailty on the Diagnosis and Management of Lung Cancer in Older Patients
  • Addressing an Invisible Epidemic: Lung Cancer in Women
  • Lung Cancer in Interstitial Lung Disease: An Emerging Dilemma
  • Challenges of Diagnosing and Treating Lung Cancer in ILD
  • ROSE It Yourself
  • Endobronchial Ultrasound: Understand TNM-8 Nodal Staging and Improve Your Yield?
  • Pulmonary Toxicities of Immune Checkpoint Inhibitors (ICI)

Supported in part by an independent grant from AstraZeneca Pharmaceuticals LP and a continuing education grant from Merck Sharp & Dohme Corp.

  • Treatment of Pulmonary Arterial Hypertension: Why Is It So Complicated?
  • Diagnostics and Management of Pulmonary Hypertension: What NOT to Do
  • Is My Patient’s Pulmonary Hypertension Left or Right? The Probe and the Catheter Come to Your Rescue
  • The Crashing Pulmonary Arterial Hypertension Patient: An Intensivist’s Nightmare
  • Too Much of a Good Thing or Not Enough? Treating Scleroderma With ILD and PH: A Pro-Con Debate
  • Oxygen Therapy: Patients’ Perspective Virtual Patient Tour

Supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc. and United Therapeutics Corporation.

  • Cystic Fibrosis Pulmonary Exacerbations: What Should Every Pulmonologist Know?
  • Lung Transplantation Referral 101: What You Need for the Boards and the Wards
  • Airway Clearance Therapy – Interactive Educational Game

Supported in part by an educational grant from Chiesi USA, Inc. and a scientific and educational grant from Vertex Pharmaceuticals Incorporated.

  • Treating NTM Lung Infections Based on the 2020 Guidelines
  • Bronchiectasis: Beyond Cystic Fibrosis
  • Optimal Therapy for Patients With Bronchiectasis: Pro/Con Debate
  • Obstructive Lung Diseases in Women – Is There a Difference?
  • Approach to Pulmonary Disease in the Geriatric Patient

Supported in part by an educational grant from Insmed.

  • New CAP Guidelines – What Changed?
  • Opportunistic Pneumonias in Immunocompromised Hosts: Understanding the Risk in Non-HIV Patients
  • Critical Care Year in Review II

Supported in part by a continuing education grant from Merck Sharp & Dohme Corp.